Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 75Genitourinary 29Breast 25Gastrointestinal 20Thoracic 13Tumor-Agnostic 12CNS 12Other solid neoplasm 11Sarcoma 7Head & Neck 6Dermatologic 4Lymphoid 2Other hematologic neoplasm 1Endocrine 1Classical hematology 1

Conditions

Melanoma 3Uveal Melanoma 1Urologic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × niraparib × Dermatologic × Clear all
NCT05169437 2025-10-29

PAVO

Tempus AI

Phase 2 Terminated
22 enrolled 17 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT03207347 2023-09-15

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

University of Florida

Phase 2 Completed
37 enrolled 15 charts
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma

NCT03925350 2021-10-22

Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

California Pacific Medical Center Research Institute

Phase 2 Unknown
41 enrolled
Dermatologic

Melanoma

NCT01294735 2012-08-15

Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

Merck Sharp & Dohme LLC

Phase 1 Completed
19 enrolled
CNSDermatologic

Glioblastoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡